By Noam Harel In the ever-changing landscape of the pharmaceutical industry, the integration of generative artificial intelligence (AI) holds immense promise and potential alongside risk, patient and consumer safety and tight regulation. Generative AI refers to the ability of machines to autonomously create new and unique content, ideas, or solutions.

By Noam Harel In the fast-paced and ever-evolving business landscape, innovation has become the lifeblood of success. Yet, many organizations fail to harness the full potential of innovation due to a significant gap between their business units. This gap, like a hidden chasm, prevents the sharing of best practices, stifling growth and hindering progress.

Ship Android apps faster than ever. Our new features allow you to effortlessly integrate with your Google Account, create production releases and release directly to the Google Play Store. Read more on this, and what's coming next.

As generative AI continues to captivate attention with its transformative potential, there is a danger that traditional AI and ML become overshadowed. But as I mentioned in my last blog, this would be a mistake as traditional AI methods still hold immense value and relevance, and likely more so than generative AI in the near term.

One of the largest health insurance providers in the United States uses Unravel to ensure that its business-critical data applications are optimized for performance, reliability, and cost in its development environment—before they go live in production. Data and data-driven statistical analysis have always been at the core of health insurance.

I am excited to share that Tricentis has acquired Waldo, a mobile test automation platform. Waldo complements and extends our existing Tricentis mobile testing offerings with new test automation capabilities that will allow our customers to deliver higher quality mobile applications.